Syndopa CR 250 MG (Carbidopa/Levodopa)

Syndopa CR 250 mg is a controlled-release formulation that contains Levodopa and Carbidopa, used for the treatment of Parkinson’s disease and Parkinson-like symptoms. Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted into dopamine to restore normal motor function. Carbidopa prevents the breakdown of Levodopa before it reaches the brain, enhancing its effectiveness and reducing side effects like nausea.

The controlled-release (CR) formulation ensures a steady and prolonged release of the medication, which helps in managing “wearing-off” symptoms and reducing fluctuations in movement control throughout the day. Syndopa CR 250 mg is typically prescribed to patients who need longer symptom control between doses. It should be taken as directed by a physician, preferably at consistent times daily. Do not crush or chew the tablets. With regular use, Syndopa CR supports improved mobility, better daily functioning, and enhanced quality of life for those living with Parkinson’s disease.